Brainstorm Cell Therapeutics Inc.
BCLI
Rank in Stocks
#28470
Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to... Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to the development and commercialization of personalized, autologous cellular therapies. These innovative treatments are specifically designed to address neurodegenerative diseases. At the heart of its strategy is the proprietary NurOwn cell therapy platform. This platform employs sophisticated cell culture techniques to prompt mesenchymal stem cells, derived from the patient's own bone marrow, to produce high concentrations of neurotrophic factors. This process aims to regulate neuroinflammatory and neurodegenerative disease mechanisms, bolster the survival of neurons, and ultimately enhance neurological function. NurOwn is currently undergoing significant clinical development, having completed a Phase III clinical trial for Amyotrophic Lateral Sclerosis (ALS). Additionally, it has successfully advanced through Phase II clinical trials for both progressive multiple sclerosis and Alzheimer's disease, with potential applications being explored for other neurodegenerative conditions. To support its therapeutic pipeline, the company has established a manufacturing partnership with Catalent for NurOwn. Incorporated in 2000, the company initially operated as Golden Hand Resources Inc. before adopting the name Brainstorm Cell Therapeutics Inc. in November 2004. Its corporate headquarters are situated in New York, New York.
Share Price
$0.99
Last synced: 2026-11-11
Market Cap
$10.92M
Change (1 day)
1.76%
Change (1 year)
54.69%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Brainstorm Cell Therapeutics Inc. (BCLI)
Category
Healthcare
Number of shares outstanding for Brainstorm Cell Therapeutics Inc. (BCLI)
Number of shares outstanding as of June 2026: 11.03M
According to Brainstorm Cell Therapeutics Inc.'s latest financial reports, its current number of shares outstanding is 11.03M. At the end of 2025 the company had 9.27M shares outstanding. The number of shares outstanding usually changes with stock splits and share buybacks.
Shares outstanding history for Brainstorm Cell Therapeutics Inc. (BCLI) from 2002 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 11.03M | 19.05% |
| 2025 | 9.27M | 74.56% |
| 2024 | 5.31M | 38.31% |
| 2023 | 3.84M | 57.02% |
| 2022 | 2.45M | 0.84% |
| 2021 | 2.42M | 7.40% |
| 2020 | 2.26M | 32.41% |
| 2019 | 1.70M | 22.86% |
| 2018 | 1.39M | 9.75% |
| 2017 | 1.26M | 1.52% |
| 2016 | 1.25M | 0.90% |
| 2015 | 1.23M | 10.88% |
| 2014 | 1.11M | -89.63% |
| 2013 | 10.74M | 116,962.37% |
| 2012 | 9.17K | -99.89% |
| 2011 | 8.01M | 34.82% |
| 2010 | 5.94M | 45.70% |
| 2009 | 4.08M | 24.69% |
| 2008 | 3.27M | 67.50% |
| 2007 | 1.95M | 23.45% |
| 2006 | 1.58M | 27.60% |
| 2005 | 1.24M | 8.70% |
| 2004 | 1.14M | -15.35% |
| 2003 | 1.35M | 650.00% |
| 2002 | 179.56K | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.50M | 2,197.28% |
US
|
|
| 401.00M | 3,533.97% |
US
|
|
| 478.91M | 4,240.02% |
AU
|
|
| 0.00 | -100.00% |
BE
|
|
| 62.74M | 468.52% |
NL
|
Questions about Brainstorm Cell Therapeutics Inc.'s number of shares outstanding
What is Brainstorm Cell Therapeutics Inc.'s number of shares outstanding?
Brainstorm Cell Therapeutics Inc.'s number of shares outstanding is 11.03M, as of Jun 2026.
What was Brainstorm Cell Therapeutics Inc.'s number of shares outstanding in 2025?
In 2025, Brainstorm Cell Therapeutics Inc.'s number of shares outstanding was 9.27M, 74.56% more than in 2024 (5.31M).
How has Brainstorm Cell Therapeutics Inc.'s number of shares outstanding changed since 2020?
From 2020 to 2025, Brainstorm Cell Therapeutics Inc.'s number of shares outstanding went from 2.26M to 9.27M, an average growth of 32.64% a year.